FDA dissociates Fosamax from fracturesMarch 12th, 2010 - 10:38 pm ICT by Pen Men At Work
Mar 12 (Pen Men at Work): American watchdogs have declared that they have not discovered any association between oral bisphosphonate osteoporosis medicines such as Merck & Co Inc.’s Fosamax and some thigh bone fissures.
The U.S. Food and Drug Administration (FDA) released its proclamation on Wednesday subsequent to the circulation of case reports of uncharacteristic subtrochanteric femur fractures — or fractures in the bone just beneath the hip joint — in ladies with osteoporosis consuming oral bisphosphonates. Bisphosphonates are a category of drugs, which are focused on thwarting bone breakages and counterbalancing bone loss connected with menopause. They include Fosamax, Roche Holding AG’s Boniva, Novartis’ Reclast and Warner Chilcott’s Actonel.
In June 2008, the FDA demanded data from all bisphosphonate drug manufacturers connected to these sorts of breakage. The organization held that an appraisal of the facts did not illustrate an augmented menace for women utilizing the medications. The FDA mentioned that, although its examination of the data did not explain a comprehensible relationship between bisphosphonates and nonconforming subtrochanteric femur fractures, the agency is running closely with outside specialists to achieve more insightfulness into the matter.
Bisphosphonates, which have existed in the marketplace for more or less a decade, had been associated with security concerns some time ago, including jeopardizing the heart.
In January, a Manhattan federal judge refused to dismiss a lawsuit alleging that Fosamax caused damage to the jaw of a female for the period of nearly eight years she made use of the pill. Merck has had to deal with a wide range of lawsuits involving just about 900 cases by patients, who have alleged that Fosamax led to the osteonecrosis of the jaw, or demise of the jawbone tissue.
Merck spokesperson, Ron Rogers, uttered in a declaration that, in scientific studies, Fosamax has not been allied with enlarged fracture threat at any skeletal location. Rogers observed that little energy femoral shaft and subtrochanteric fissures have been reported in the health literature as taking place in non-bisphosphonate consumers. He also stated that Merck is, at this time, performing studies to additionally explore the question of low energy femoral shaft and subtrochanteric breakages.
The FDA counseled that the patients keep swallowing their pills unless told not to do so by their medical doctor. It also suggested that healthcare professionals be conscious of a potential hazard of unusual subtrochanteric femur fractures in patients gobbling oral bisphosphonates.
- Keep tab on osteoporosis pain-reliever: Experts (Oct 20 is World Osteoporosis Day) - Oct 19, 2011
- Osteoporosis drugs can raise fracture risk - Oct 17, 2010
- FDA Puts Fosamax Under Scanner - Mar 12, 2010
- Long-term use of osteoporosis drugs raises risk of fractures - Feb 23, 2011
- Drugs to fight bone thinning double cancer risk - Sep 03, 2010
- Bone loss drugs may cut breast cancer risk - Mar 03, 2010
- FDA rejects combo cholesterol drug - Mar 07, 2012
- Wine could help protect older women from thinning bones - Aug 03, 2012
- Postmenopausal women urged to increase yearly dental checkups - Mar 11, 2011
- Osteoporosis drug 'doubles cancer risk' - Sep 03, 2010
- Now, just one bone-building jab is all it takes to cure osteoporosis - Apr 23, 2011
- Pioneering surgery rebuilds tumour ravaged face - Sep 09, 2012
- Osteoporosis treatment gives patients an extra 5 years of life - Feb 03, 2011
- Bone Strenghthening Drugs Increases Throat Cancer Risk, Study Reveals - Sep 07, 2010
- Heartburn pills 'can raise osteoporosis risk' - May 29, 2010
Tags: bisphosphonates, bone loss, boniva, case reports, drug manufacturers, food and drug administration, food and drug administration fda, fosamax, jawbone, men at work, merck co, merck co inc, nonconforming, novartis reclast, osteonecrosis of the jaw, pen men, roche holding ag, ron rogers, thigh bone, warner chilcott